Agenda


The full agenda will be updated with speakers and companies over the coming weeks. All times in British Summer Time (BST)


LIVE = Real-time content with audience Q&A (becomes on-demand once held)
ON-DEMAND = Evergreen content that can be watched anytime to fit around your schedule
INTERACTIVE = Live, peer-to-peer grouped sessions allowing multi-way discussion
1:1 PARTNERING = Private and secure video-enabled networking and meeting

 

Day 1 - 15 September

09:00

ON-DEMAND: SHOWCASES AND VIRTUAL TECH DEMO BOOTHS (available all-day)

09:10

LIVE: EXECUTIVE PANEL (40 Mins): Finding, funding and building Europe’s next healthtech wave

European digital health and healthtech have seen unprecedented growth in recent years, buoyed by regulatory breakthroughs, commitments to transformation agendas from prominent regulators and policy makers, and increased traction with payers, providers, and commercial leaders. Investment has been a crucial driver of healthcare transformation and looked set to continue into the new decade - before COVID-19 hit. But while the pandemic has disrupted investment and deal-flow, it has also validated as never before the necessity of a digitised healthcare sector. A panel of European investors discuss and debate the challenges now facing European digital health innovation, the opportunities to be grasped, and how innovators and can continue to attract investment and partnerships during and post-COVID-19.

  • Patrik Soboki, Partner, Industrifonden
  • Josep Sanfeliu, Co-Founder and Managing Partner, Asabys Partners 
  • David Germonpré, Investment Partner, MTIP
  • Rebecca Hunt, Investor, Octopus Ventures
10:00

1:1 PARTNERING OPENS (24Hrs)

12:00

ON-DEMAND: EXECUTIVE PANEL (40 Mins): Forging successful pharma-innovator partnerships

Partnerships with health-tech start-ups have become a key strategy for global pharma to bringing treatments and interventions to market across a variety of verticals. Successful partnerships enable start-ups to scale faster, pharma to better engage patients, and patients to benefit from more user friendly and efficacious products. A panel of pharma digital health and innovation heads share war stories, discuss successful partnerships models, and consider the impact of the COVID-19 on the innovation landscape.

  • Olivier Gien, Global Head of Digital Portfolio and Operations, Sanofi
  • Anders Dyhr Toft, Corporate Vice President Commercial Innovation, Novo Nordisk
  • Lauren Li, Head of Digital Health, Ipsen
  • Robin Blackburn, VP Global Innovation Incubator, Merck and Co.
12:45

INTERACTIVE: EXECUTIVE FORUM: Pharma Digital Leaders Forum  (1hr 40Mins)

The Pharma Digital Leaders Forum is an invite-only leaders’ roundtable forum, in which those leading the charge on digital transformation and innovation initiatives at global pharma share their experiences, discuss their collective challenges and look ahead at future developments and actionable outcomes.

14:30

ON-DEMAND: EXECUTIVE PANEL (40 Mins): Transforming and reimagining healthcare

Healthtech innovation has reached a climax over the last decade, and the leaders of the world’s increasingly complex healthcare ecosystems are ready to respond. But significant hurdles remain, from value-alignment adoption, reimbursement, to effective collaboration between stakeholders – all challenges which the COVID-19 crisis has accentuated by accelerating healthcare’s digitalisation and demonstrating the need for well-connected healthcare ecosystems. A panel of innovation leaders across health systems, pharma, medical technology and investment, discuss the state of health tech innovation, where we’re headed, and the collaborations and realignments necessary to get us there.

  • Jeroen Tas, Chief Innovation Officer, Philips
  • Frank Yu, CEO, Ally Bridge Group
15:15

LIVE: EXECUTIVE PANEL (40 Mins): Post Covid-19, is healthcare’s new normal digital?

Even before COVID-19 forced swathes of the global economy into shutdown and created an unprecedented public health crisis, digital health transformation was front and centre for healthcare and life science sectors. Now, with contact tracing a necessity, telemedicine entering a new epoch, and unprecedented collaboration between key stakeholders defining response efforts, digital health is more important than ever before. A panel of healthcare executives at the forefront of innovative COVID-19 response efforts discuss the impact of COVID-19 on digital health adoption and how healthcare will be re-shaped by the pandemic.

  • Jennifer Schneider, President, Livongo 
  • Mark Davies, Chief Medical Officer EMEA, IBM Watson Health
  • John Brownstein, Chief Innovation Officer, Boston Children’s Hospital
  • Yian Yang, Senior Director, Digital Health, Eli Lilly
16:00

LIVE: GOLD SHOWCASE SPOTLIGHT (10 Mins)

16:10

LIVE: SILVER SHOWCASE SPOTLIGHT (10 Mins)

16:20

LIVE: BRONZE SHOWCASE SPOTLIGHT (10 Mins)

16:30

INTERACTIVE: VIRTUAL NETWORKING RECEPTION

Day 2 - 16 September

09:00

ON-DEMAND: SHOWCASES AND VIRTUAL TECH DEMO BOOTHS (available all-day)

09:10

LIVE: EXECUTIVE PANEL (40 Mins): Is Healthtech still attractive to corporate venture capital?

Corporate venture capital has proven to be an essential resource for the developing digital health ecosystem and a vehicle for key stakeholders from diverse verticals to drive synergistic innovations across the healthcare value chain. But in light of the major challenges and opportunities currently facing both healthtech start-ups and commercial leaders across the worlds of life science, insurance, tech and consumer health, are corporate venture investors expanding into new areas or consolidating existing portfolio focuses, and how can healthtech SMEs demonstrate value to corporate investors in the current climate? A panel of CVC investors explore the current innovation landscape and debate the best strategies to drive value across different verticals.

  • David Gordon, Head of Investments, Longliv Ventures 
  • Edward Kliphuis, Director, M Ventures 
  • Bruce Meadows, Investment Director, Takeda Digital Ventures
  • Tamir Meiri, Senior Manager Venture Investments, J&J
10:00

1:1 PARTNERING RE-OPENS (24Hrs)

12:00

ON-DEMAND: EXECUTIVE PANEL (40 Mins): Incubating and accelerating innovation

Europe’s fragmented health systems pose a diverse set of challenges for digital health entrepreneurs around reimbursement mechanisms, sustainable funding, scalability and more. But with an increasing number of digital health SMEs successfully gaining traction with investors, payers and providers, and entering multiple markets, Europe remains a huge opportunity for global healthcare innovators. A panel of leading digital health investors, accelerators and incubators discuss the existing and emergent opportunities for European health tech innovation and how key stakeholders can collaborate and partner to transform Europe’s healthcare ecosystems.

  • Jan-Philipp Beck, CEO, EIT Health
  • Ben Maruthappu, CEO, Cera Care and Co-Founder NHS Innovation Accelerator
  • Julia Belaya, Global Head of Business Development for Health, Plug and Play Tech Centre
12:45

INTERACTIVE: ZOOM HOSTED CEO FORUM (1hr 40Mins)

14:30

ON-DEMAND: EXECUTIVE PANEL (40 Mins): The Payer-Provider perspective on digital health partnerships and adoption

Collaboration and buy-in from payers and providers constitute a key lynchpin in the adoption of digital health tools and technologies by health systems globally. But navigating these systems is no simple task, and innovators looking for adoption must consider numerous factors, from clinician workflows to alignment of financial and clinical value and reimbursement procedures. A panel of international payers and providers discuss their approaches to innovator partnerships, and key success factors for digital tools, platforms and technologies in established healthcare ecosystems.

15:15

LIVE: EXECUTIVE PANEL (40 Mins): Navigating the new healthtech funding landscape

After two record breaking years of digital health investment, deal-flow and commercial milestones, innovation has indisputably been hit by the COVID-19 pandemic. Yet it’s also clear that the current crisis is prompting a fundamental shift in favour of digital health by exposing weak points in healthcare supply chains, creating an urgent use-case or RWE platforms, and demonstrating beyond doubt the importance of digital platforms and patient-provider connectivity. What impact has COVID-19 had on investment strategies and where are the opportunities for innovative solutions to emerge?

  • Anat Naschitz, Managing Director, Orbimed
  • Jessica Federer, Partner, Boston Millennia Partners
  • Steve Tolle, Partner, HLM Ventures
  • David Kim, Managing Partner, DigiTx Partners
16:00

ON-DEMAND: GOLD SHOWCASE SPOTLIGHT

16:10

ON-DEMAND: SILVER SHOWCASE SPOTLIGHT 

16:20

ON-DEMAND: BRONZE SHOWCASE SPOTLIGHT 

16:30

INTERACTIVE: INVESTOR SYNDICATION NETWORKING RECEPTION

 

Day 3 - 17 September

09:00

1:1 PARTNERING RE-OPENS (24 Hrs)


ON-DEMAND: ALL PANEL CONTENT FROM DAY 1 & 2 

ON-DEMAND: SHOWCASES AND VIRTUAL TECH DEMO BOOTHS (available all-day)


INTERACTIVE: VIRTUAL NETWORKING RECEPTION

Day 4 - 18 September

09:00

1:1 PARTNERING RE-OPENS (24 Hrs)


ON-DEMAND: ALL PANEL CONTENT FROM DAY 1 & 2 

ON-DEMAND: SHOWCASES AND VIRTUAL TECH DEMO BOOTHS (available all-day)